Log In
Print
BCIQ
Print
Print this Print this
 

tanezumab (PF-4383119, RN 624, RN-624) (formerly RI 624)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHumanized mAb against nerve growth factor (NGF)
Molecular Target Nerve growth factor (NGF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsTreat cancer pain; Treat chronic low back pain; Treat chronic low back pain and painful diabetic peripheral neuropathy (DPN); Treat chronic pain; Treat chronic pain due to interstitial cystitis; Treat chronic pain due to osteoarthritis (OA) of the knee; Treat osteoarthritis (OA); Treat pain due to osteoarthritis (OA) of the knee
Regulatory Designation

Partner

Eli Lilly and Co.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today